N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Conditions
Keywords
Cutaneous Melanoma, Dacarbazine, Pimasertib, N-Ras
Brief summary
This is a Phase 2, multicenter, randomized, controlled, open-label trial of pimasertib versus dacarbazine aimed to confirm the activity of pimasertib in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma by comparing the progression-free survival (PFS) of subjects treated with either pimasertib or dacarbazine and by getting a better understanding of the efficacy, safety, pharmacogenomics (PGx) and their relationship with pimasertib exposure.
Interventions
DRUGPimasertib
Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
DRUGDacarbazine
Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
Sponsors
Merck KGaA, Darmstadt, Germany
EMD Serono
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects with measurable, histologically or cytologically confirmed, locally advanced or metastatic cutaneous melanoma (stage III c or M1ac) N-Ras mutated. If N-Ras mutational status is unknown at screening, it must be prospectively defined before inclusion. If N-Ras mutational status is already known before screening, it must be retrospectively confirmed after inclusion by the sponsor. * Tumor lesions amenable to biopsy or available tumor tissue as archival samples. * Age greater than or equal to (\>=) 18 years. * Has read and understood the informed consent form and is willing and able to give informed consent. Fully understands requirements of the trial and willing to comply with all trial visits and assessments. * Women of childbearing potential must have a negative blood pregnancy test at the screening visit. For the purposes of this trial, women of childbearing potential are defined as: All female subjects after puberty unless they are post-menopausal for at least two years, or are surgically sterile. * Female subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for 2 weeks prior to, during and four weeks after the last dose of trial medication. Effective contraception is defined as the method of contraception with a failure rate of less than 1% per year. Adequate contraception is defined as follows: two barrier methods or one barrier method with a spermicidal or intrauterine device or oral contraception for female partners of male subjects.
Exclusion criteria
* Has previous systemic treatment for locally advanced or metastatic cutaneous melanoma (excluding adjuvant treatment). * Has non-measurable lesions, disease not evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 * Has an Eastern Cooperative Oncology Group performance status (ECOG PS) \>1. * Has bone marrow impairment as evidenced by Hemoglobin \<10.0 g/dL, Neutrophil count \<1.5 \* 10\^9/L, platelets \<100 \* 10\^9/L. * Has renal impairment as evidenced by calculated creatinine clearance \<60 mL/min (according to the Cockcroft-Gault formula). * Has liver function abnormality as defined by total bilirubin \>1.5 \* Upper Limit of Normal (ULN), or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \>2.5 \* ULN, for subjects with liver involvement AST/ALT \>5 \* ULN. * Has significant cardiac conduction abnormalities, including QTc prolongation of \>480 milliseconds and/or pacemaker or clinically relevant impaired cardiovascular function. * Has hypertension uncontrolled by medication * Has retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), history of uveitis, or history of retinal vein occlusion (RVO) or any eye condition that would be considered a risk factor for RVO (e.g., uncontrolled glaucoma or ocular hypertension). * Has known active central nervous system (CNS) metastases unless previously radiotherapy treated, stable by CT scan for at least 3 months without evidence of cerebral edema and no requirements for corticosteroids or anticonvulsants. * History of difficulty swallowing, malabsorption or other chronic gastro-intestinal disease, or conditions that may hamper compliance and/or absorption of the tested product. * Known human immunodeficiency virus (HIV) positivity, active hepatitis C, or active hepatitis B. * Has undergone surgical intervention within 28 days from Day 1 of trial drug treatment. * Has received extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years from Day 1 of trial drug treatment. * Has history of any other significant medical disease such as major gastric or small bowel surgery, recent drainage of significant volumes of ascites or pleural effusion or has a psychiatric condition that might impair the subject well-being or preclude full participation in the trial. * Has known hypersensitivity to dacarbazine. * Is a pregnant or nursing female. * Participated in another clinical trial within the past 28 days. * Has creatine phosphokinase (CPK) level at baseline National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade \>=2 (i.e \> 2.5 \* ULN), and/or has a previous history of myositis or rhabdomyolysis. * Is suitable for treatment with an approved B-Raf inhibitor (
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015) | PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment (otherwise censored), whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate (DCR) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015) | DCR was defined as the percentage of subjects with CR, PR, or stable disease (SD) for greater than (\>) 3 months assessed by investigator according to RECIST version 1.1. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \<10 mm. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
| Percentage of Subjects With Progression-free Survival (PFS) at 6 Months | 6 months | PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions. Percentage of Subjects with PFS at 6 Months were reported. |
| Overall Survival (OS) | From date of randomization until date of death from any cause, assessed up to cut-off date (04-Jul-2015) | OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date. |
| Percentage of Subjects With Overall Survival (OS) at 12 Months | 12 months | OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date. Percentage of Subjects with OS at 12 months were reported. |
| Objective Response Rate (ORR) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015) | ORR was defined as the percentage of subjects with complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions. |
| Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Baseline, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 35, 36, 37 and EOT (up to cut-off date [04-Jul-2015]) | QoL assessed using FACT-M assessment tool. This includes 27-item FACT-G questionnaire which consists of 24 questions; 7 relating to PWB, 7 relating to SWB, 6 relating to EWB and 7 relating to FWB. Also, it includes melanoma-specific subscale consists of 16 questions for MS and 8 questions for the MSS. Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Trial Outcome Index (FACT-M TOI) ranges from 0 to a high of 120 and is derived as: FACT-M TOI = PWB Score + FWB Score +MS Score. Higher scores represent a better quality of life. |
| Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | Baseline up to cut-off date (04-Jul-2015) | AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 33 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs. TEAEs were to be reported separately for dacarbazine, pimasertib and pimasertib (crossover) reporting arms. |
| Number of Subjects With Adverse Events (AEs) of Special Interest | Baseline up to cut-off date (04-Jul-2015) | Adverse events of special interest included ocular retinal vein occlusion, serious retinal detachment or similar retinal abnormality characterized by accumulation of serous fluid in the retina, creatine phosphokinase (CPK) elevation and isoenzyme TEAE of Special Interest (Grade \>=2) and acute renal failure (Grade \>=2). Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease. |
| Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | Baseline up to cut-off date (04-Jul-2015) | Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease. |
| Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Baseline, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 35, 36, 37 and EOT (up to cut-off date [04-Jul-2015]) | QoL assessed using Function Assessment Cancer Therapy-melanoma (FACT-M) assessment tool. This includes 27-item FACT-General (FACT-G) questionnaire which consists of 24 questions;7 relating to physical well-being (PWB),7 relating to social/family well-being (SWB),6 relating to emotional well-being (EWB) and 7 relating to functional well-being (FWB). Also, it includes melanoma-specific subscale consists of 16 questions for Melanoma Subscale (MS) and 8 questions for Melanoma Surgery Scale (MSS).Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Total Score (FACT-M TS) ranges from 0 to 172 and is derived as follows: FACT-M TS= PWB Score + SWB Score + EWB Score + FWB Score + MS Score. Higher scores represent a better quality of life. |
Countries
Australia, Belgium, France, Germany, Israel, Italy, Netherlands, New Zealand, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States
Participant flow
Recruitment details
First/last subject (informed consent): 05 December 2012/04 June 2014. Cut-off date: 04 July 2015. Last subject last visit: 24 October 2016.
Pre-assignment details
A total of 194 subjects were randomized in trial. Data presented based on the cut-off date of 04 July 2015.
Participants by arm
| Arm | Count |
|---|---|
| Dacarbazine Subjects received dacarbazine intravenously at dose of 1000 mg/m\^2 of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurred first. Eligible subjects with documented tumor progression on dacarbazine were offered to switch to pimasertib treatment. | 64 |
| Pimasertib Subjects received pimasertib orally as monotherapy at a dose of 60 mg twice daily continuously. Treatment consisted of repeated 21-day cycles which was continued until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurred first. | 130 |
| Total | 194 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Cross-over (Dacarbazine To Pimasertib) | On-study | 0 | 0 | 1 |
| Randomization Period | On-study | 2 | 5 | 0 |
Baseline characteristics
| Characteristic | Dacarbazine | Pimasertib | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 28 Participants | 65 Participants | 93 Participants |
| Age, Categorical Between 18 and 65 years | 36 Participants | 65 Participants | 101 Participants |
| Sex: Female, Male Female | 28 Participants | 62 Participants | 90 Participants |
| Sex: Female, Male Male | 36 Participants | 68 Participants | 104 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 59 / 61 | 130 / 130 | 41 / 41 |
| serious Total, serious adverse events | 12 / 61 | 74 / 130 | 26 / 41 |
Outcome results
Primary
Progression Free Survival (PFS)
PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment (otherwise censored), whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)
Population: ITT analysis set included all subjects who were randomized to trial treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dacarbazine | Progression Free Survival (PFS) | 6.86 weeks |
| Pimasertib | Progression Free Survival (PFS) | 13.00 weeks |
p-value: 0.002295% CI: [0.42, 0.83]Stratified Log Rank Test
Secondary
Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)
QoL assessed using Function Assessment Cancer Therapy-melanoma (FACT-M) assessment tool. This includes 27-item FACT-General (FACT-G) questionnaire which consists of 24 questions;7 relating to physical well-being (PWB),7 relating to social/family well-being (SWB),6 relating to emotional well-being (EWB) and 7 relating to functional well-being (FWB). Also, it includes melanoma-specific subscale consists of 16 questions for Melanoma Subscale (MS) and 8 questions for Melanoma Surgery Scale (MSS).Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Total Score (FACT-M TS) ranges from 0 to 172 and is derived as follows: FACT-M TS= PWB Score + SWB Score + EWB Score + FWB Score + MS Score. Higher scores represent a better quality of life.
Time frame: Baseline, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 35, 36, 37 and EOT (up to cut-off date [04-Jul-2015])
Population: ITT analysis set. Here Number of Subjects Analyzed = subjects evaluable for this outcome and Number Analyzed = subjects evaluable at specified time points for each arm, respectively. There were no subjects analyzed at certain time points (that is, Number Analyzed = 0) because there was no data collected for respective arms at those time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 2 | -3.05 units on a scale | Standard Deviation 14.815 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 27 | 27.00 units on a scale | — |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 3 | 0.60 units on a scale | Standard Deviation 19.965 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 28 | 27.00 units on a scale | — |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 4 | 4.11 units on a scale | Standard Deviation 14.746 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 22 | 18.00 units on a scale | Standard Deviation 12.728 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 5 | 0.62 units on a scale | Standard Deviation 11.81 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 18 | 27.00 units on a scale | — |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 6 | -3.71 units on a scale | Standard Deviation 15.674 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 23 | 27.00 units on a scale | — |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 7 | -1.10 units on a scale | Standard Deviation 13.318 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 20 | 16.00 units on a scale | Standard Deviation 15.556 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 8 | 1.28 units on a scale | Standard Deviation 12.928 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 24 | 13.50 units on a scale | Standard Deviation 19.092 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 9 | 2.21 units on a scale | Standard Deviation 16.224 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 17 | 3.00 units on a scale | Standard Deviation 5.657 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 10 | 4.40 units on a scale | Standard Deviation 14.818 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 25 | 14.50 units on a scale | Standard Deviation 17.678 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 11 | 1.02 units on a scale | Standard Deviation 19.161 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 21 | 17.00 units on a scale | Standard Deviation 14.142 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 12 | 1.56 units on a scale | Standard Deviation 19.932 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at EOT | -7.91 units on a scale | Standard Deviation 23.119 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 13 | 5.51 units on a scale | Standard Deviation 20.191 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 26 | 27.00 units on a scale | — |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 14 | 11.50 units on a scale | Standard Deviation 21.92 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Baseline | 126.20 units on a scale | Standard Deviation 23.828 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 15 | 9.60 units on a scale | Standard Deviation 15.345 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 19 | 16.50 units on a scale | Standard Deviation 14.849 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 16 | 10.56 units on a scale | Standard Deviation 14.935 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 10 | -13.26 units on a scale | Standard Deviation 20.716 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 11 | -14.10 units on a scale | Standard Deviation 21.157 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 12 | -10.52 units on a scale | Standard Deviation 18.895 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 13 | -13.38 units on a scale | Standard Deviation 23.69 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 14 | -18.24 units on a scale | Standard Deviation 22.998 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 15 | -11.33 units on a scale | Standard Deviation 19.787 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 4 | -6.54 units on a scale | Standard Deviation 19.919 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 17 | -9.18 units on a scale | Standard Deviation 24.166 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 18 | -3.92 units on a scale | Standard Deviation 9.64 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 19 | -1.15 units on a scale | Standard Deviation 8.147 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 20 | 1.17 units on a scale | Standard Deviation 5.947 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 21 | 4.17 units on a scale | Standard Deviation 8.918 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 22 | 1.32 units on a scale | Standard Deviation 11.163 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 23 | -13.69 units on a scale | Standard Deviation 15.354 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 24 | -3.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 25 | -3.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 26 | -2.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 28 | -0.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 30 | -1.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 31 | -7.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 32 | -7.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 33 | -8.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 35 | -1.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 36 | -3.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 37 | -4.83 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at EOT | -9.98 units on a scale | Standard Deviation 20.56 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Baseline | 132.24 units on a scale | Standard Deviation 22.179 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 2 | -3.06 units on a scale | Standard Deviation 18.492 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 3 | -6.77 units on a scale | Standard Deviation 21.716 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 16 | -11.18 units on a scale | Standard Deviation 23.68 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 5 | -2.81 units on a scale | Standard Deviation 17.202 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 6 | -8.45 units on a scale | Standard Deviation 20.939 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 7 | -8.84 units on a scale | Standard Deviation 19.128 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 8 | -14.67 units on a scale | Standard Deviation 18.508 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 9 | -13.67 units on a scale | Standard Deviation 21.388 |
Secondary
Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)
QoL assessed using FACT-M assessment tool. This includes 27-item FACT-G questionnaire which consists of 24 questions; 7 relating to PWB, 7 relating to SWB, 6 relating to EWB and 7 relating to FWB. Also, it includes melanoma-specific subscale consists of 16 questions for MS and 8 questions for the MSS. Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Trial Outcome Index (FACT-M TOI) ranges from 0 to a high of 120 and is derived as: FACT-M TOI = PWB Score + FWB Score +MS Score. Higher scores represent a better quality of life.
Time frame: Baseline, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 35, 36, 37 and EOT (up to cut-off date [04-Jul-2015])
Population: ITT analysis set. Here Number of Subjects Analyzed = subjects evaluable for this outcome and Number Analyzed = subjects evaluable at specified time points for each arm, respectively. There were no subjects analyzed at certain time points (that is, Number Analyzed = 0) because there was no data collected for respective arms at those time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 17 | 2.50 units on a scale | Standard Deviation 0.707 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 4 | 1.54 units on a scale | Standard Deviation 10.304 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 18 | 3.00 units on a scale | — |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 9 | -1.93 units on a scale | Standard Deviation 6.3 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 19 | 2.50 units on a scale | Standard Deviation 0.707 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 2 | -3.33 units on a scale | Standard Deviation 12.015 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 20 | 4.00 units on a scale | Standard Deviation 1.414 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 10 | -1.10 units on a scale | Standard Deviation 5.654 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 21 | 3.50 units on a scale | Standard Deviation 0.707 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 5 | -0.86 units on a scale | Standard Deviation 5.405 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 22 | 4.00 units on a scale | Standard Deviation 1.414 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 11 | -2.90 units on a scale | Standard Deviation 7.722 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 23 | 3.00 units on a scale | — |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Baseline | 90.35 units on a scale | Standard Deviation 19.348 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 24 | 2.50 units on a scale | Standard Deviation 0.707 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 26 | 3.00 units on a scale | — |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 12 | -2.40 units on a scale | Standard Deviation 7.408 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 27 | 3.00 units on a scale | — |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 28 | 3.00 units on a scale | — |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 6 | -3.29 units on a scale | Standard Deviation 7.752 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 13 | 0.80 units on a scale | Standard Deviation 7.697 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 3 | -0.69 units on a scale | Standard Deviation 15.974 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 14 | 0.00 units on a scale | Standard Deviation 4.243 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 7 | -2.07 units on a scale | Standard Deviation 6.859 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 15 | 1.60 units on a scale | Standard Deviation 4.084 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 25 | 3.50 units on a scale | Standard Deviation 0.707 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 16 | 0.61 units on a scale | Standard Deviation 3.994 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at EOT | -8.18 units on a scale | Standard Deviation 16.41 |
| Dacarbazine | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 8 | 0.83 units on a scale | Standard Deviation 5.161 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 32 | -4.00 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 33 | -3.00 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 35 | 0.00 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 36 | 0.00 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 37 | -3.00 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 24 | -2.00 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at EOT | -10.42 units on a scale | Standard Deviation 16.256 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 25 | -1.00 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Baseline | 94.07 units on a scale | Standard Deviation 17.534 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 2 | -4.40 units on a scale | Standard Deviation 14.286 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 3 | -7.99 units on a scale | Standard Deviation 17.089 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 4 | -7.97 units on a scale | Standard Deviation 16.741 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 5 | -4.37 units on a scale | Standard Deviation 14.084 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 6 | -9.15 units on a scale | Standard Deviation 18.813 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 7 | -8.99 units on a scale | Standard Deviation 14.783 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 8 | -15.09 units on a scale | Standard Deviation 14.458 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 9 | -13.79 units on a scale | Standard Deviation 17.198 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 10 | -12.37 units on a scale | Standard Deviation 17.058 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 11 | -13.95 units on a scale | Standard Deviation 17.006 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 12 | -11.95 units on a scale | Standard Deviation 17.311 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 13 | -13.57 units on a scale | Standard Deviation 21.699 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 14 | -18.55 units on a scale | Standard Deviation 19.88 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 15 | -13.59 units on a scale | Standard Deviation 15.747 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 16 | -13.15 units on a scale | Standard Deviation 19.13 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 17 | -10.66 units on a scale | Standard Deviation 20.007 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 18 | -5.72 units on a scale | Standard Deviation 4.614 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 19 | -4.94 units on a scale | Standard Deviation 5.238 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 20 | -2.33 units on a scale | Standard Deviation 1.155 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 21 | 0.00 units on a scale | Standard Deviation 2 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 22 | -1.40 units on a scale | Standard Deviation 3.831 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 23 | -13.36 units on a scale | Standard Deviation 16.061 |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 26 | 0.00 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 28 | 1.00 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 30 | 1.00 units on a scale | — |
| Pimasertib | Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT) | Change at Day 1 Cycle 31 | -3.00 units on a scale | — |
Secondary
Disease Control Rate (DCR)
DCR was defined as the percentage of subjects with CR, PR, or stable disease (SD) for greater than (\>) 3 months assessed by investigator according to RECIST version 1.1. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \<10 mm. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)
Population: ITT analysis set included all subjects who were randomized to trial treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dacarbazine | Disease Control Rate (DCR) | 15.6 percentage of subjects |
| Pimasertib | Disease Control Rate (DCR) | 33.1 percentage of subjects |
Secondary
Number of Subjects With Adverse Events (AEs) of Special Interest
Adverse events of special interest included ocular retinal vein occlusion, serious retinal detachment or similar retinal abnormality characterized by accumulation of serous fluid in the retina, creatine phosphokinase (CPK) elevation and isoenzyme TEAE of Special Interest (Grade \>=2) and acute renal failure (Grade \>=2). Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease.
Time frame: Baseline up to cut-off date (04-Jul-2015)
Population: Safety analysis set (SAF) consisted of all subjects who received at least 1 dose of any trial treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dacarbazine | Number of Subjects With Adverse Events (AEs) of Special Interest | Retinal vein occlusion | 0 subjects |
| Dacarbazine | Number of Subjects With Adverse Events (AEs) of Special Interest | Serious retinal detachment | 0 subjects |
| Dacarbazine | Number of Subjects With Adverse Events (AEs) of Special Interest | CPK/Isoenzyme TEAE of Special Interest (>=Grade 2) | 0 subjects |
| Dacarbazine | Number of Subjects With Adverse Events (AEs) of Special Interest | Acute renal failure (Grade >= 2) | 1 subjects |
| Pimasertib | Number of Subjects With Adverse Events (AEs) of Special Interest | Acute renal failure (Grade >= 2) | 9 subjects |
| Pimasertib | Number of Subjects With Adverse Events (AEs) of Special Interest | Retinal vein occlusion | 5 subjects |
| Pimasertib | Number of Subjects With Adverse Events (AEs) of Special Interest | CPK/Isoenzyme TEAE of Special Interest (>=Grade 2) | 74 subjects |
| Pimasertib | Number of Subjects With Adverse Events (AEs) of Special Interest | Serious retinal detachment | 76 subjects |
| Pimasertib (Crossover) | Number of Subjects With Adverse Events (AEs) of Special Interest | Acute renal failure (Grade >= 2) | 2 subjects |
| Pimasertib (Crossover) | Number of Subjects With Adverse Events (AEs) of Special Interest | Serious retinal detachment | 21 subjects |
| Pimasertib (Crossover) | Number of Subjects With Adverse Events (AEs) of Special Interest | CPK/Isoenzyme TEAE of Special Interest (>=Grade 2) | 24 subjects |
| Pimasertib (Crossover) | Number of Subjects With Adverse Events (AEs) of Special Interest | Retinal vein occlusion | 2 subjects |
Secondary
Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings
Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease.
Time frame: Baseline up to cut-off date (04-Jul-2015)
Population: Safety analysis set (SAF) consisted of all subjects who received at least 1 dose of any trial treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dacarbazine | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | Laboratory Parameter | 0 subjects |
| Dacarbazine | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | Vital Signs | 0 subjects |
| Dacarbazine | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | ECG | 0 subjects |
| Dacarbazine | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | Ophthalmologic Findings | 0 subjects |
| Pimasertib | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | Ophthalmologic Findings | 0 subjects |
| Pimasertib | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | Laboratory Parameter | 0 subjects |
| Pimasertib | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | ECG | 0 subjects |
| Pimasertib | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | Vital Signs | 0 subjects |
| Pimasertib (Crossover) | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | Ophthalmologic Findings | 0 subjects |
| Pimasertib (Crossover) | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | Vital Signs | 0 subjects |
| Pimasertib (Crossover) | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | ECG | 0 subjects |
| Pimasertib (Crossover) | Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings | Laboratory Parameter | 0 subjects |
Secondary
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death
AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 33 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs. TEAEs were to be reported separately for dacarbazine, pimasertib and pimasertib (crossover) reporting arms.
Time frame: Baseline up to cut-off date (04-Jul-2015)
Population: Safety analysis set (SAF) consisted of all subjects who received at least 1 dose of any trial treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dacarbazine | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | TEAEs | 60 subjects |
| Dacarbazine | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | Serious TEAEs | 12 subjects |
| Dacarbazine | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | TEAEs Leading to Discontinuation | 3 subjects |
| Dacarbazine | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | TEAEs Leading To Death | 4 subjects |
| Pimasertib | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | TEAEs Leading To Death | 6 subjects |
| Pimasertib | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | TEAEs | 130 subjects |
| Pimasertib | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | TEAEs Leading to Discontinuation | 61 subjects |
| Pimasertib | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | Serious TEAEs | 74 subjects |
| Pimasertib (Crossover) | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | TEAEs Leading To Death | 6 subjects |
| Pimasertib (Crossover) | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | Serious TEAEs | 26 subjects |
| Pimasertib (Crossover) | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | TEAEs Leading to Discontinuation | 16 subjects |
| Pimasertib (Crossover) | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death | TEAEs | 41 subjects |
Secondary
Objective Response Rate (ORR)
ORR was defined as the percentage of subjects with complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)
Population: ITT analysis set included all subjects who were randomized to trial treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dacarbazine | Objective Response Rate (ORR) | 14.1 percentage of subjects |
| Pimasertib | Objective Response Rate (ORR) | 26.9 percentage of subjects |
Secondary
Overall Survival (OS)
OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date.
Time frame: From date of randomization until date of death from any cause, assessed up to cut-off date (04-Jul-2015)
Population: ITT analysis set included all subjects who were randomized to trial treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dacarbazine | Overall Survival (OS) | 10.61 months |
| Pimasertib | Overall Survival (OS) | 8.87 months |
Secondary
Percentage of Subjects With Overall Survival (OS) at 12 Months
OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date. Percentage of Subjects with OS at 12 months were reported.
Time frame: 12 months
Population: ITT analysis set included all subjects who were randomized to trial treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dacarbazine | Percentage of Subjects With Overall Survival (OS) at 12 Months | 44.5 percentage of subjects |
| Pimasertib | Percentage of Subjects With Overall Survival (OS) at 12 Months | 43.3 percentage of subjects |
Secondary
Percentage of Subjects With Progression-free Survival (PFS) at 6 Months
PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions. Percentage of Subjects with PFS at 6 Months were reported.
Time frame: 6 months
Population: ITT analysis set included all subjects who were randomized to trial treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dacarbazine | Percentage of Subjects With Progression-free Survival (PFS) at 6 Months | 9.4 percentage of subjects |
| Pimasertib | Percentage of Subjects With Progression-free Survival (PFS) at 6 Months | 17.3 percentage of subjects |